| Primary |
| Drug Use For Unknown Indication |
23.3% |
| Onychomycosis |
13.9% |
| Product Used For Unknown Indication |
9.3% |
| Fungal Infection |
6.8% |
| Hypertension |
5.1% |
| Antifungal Prophylaxis |
4.6% |
| Febrile Neutropenia |
4.5% |
| Bronchopulmonary Aspergillosis |
4.0% |
| Prophylaxis |
3.6% |
| Aspergillosis |
3.1% |
| Pulmonary Mycosis |
3.1% |
| Diabetes Mellitus |
3.0% |
| Bronchopneumopathy |
2.9% |
| Infection |
2.3% |
| Sepsis |
1.9% |
| Chronic Obstructive Pulmonary Disease |
1.8% |
| Cystic Fibrosis |
1.8% |
| Histoplasmosis |
1.8% |
| Lung Infection |
1.8% |
| Candidiasis |
1.4% |
|
| Death |
13.2% |
| Vomiting |
8.0% |
| Weight Decreased |
8.0% |
| Weight Increased |
7.5% |
| Oedema Peripheral |
6.3% |
| Pyrexia |
5.7% |
| Drug Exposure During Pregnancy |
5.2% |
| Dyspnoea |
5.2% |
| Septic Shock |
4.6% |
| Cardiac Failure Congestive |
4.0% |
| Drug Interaction |
4.0% |
| Renal Failure Acute |
4.0% |
| Renal Impairment |
3.4% |
| Vision Blurred |
3.4% |
| Atrial Fibrillation |
2.9% |
| Chest Discomfort |
2.9% |
| Hyperbilirubinaemia |
2.9% |
| Palpitations |
2.9% |
| Sepsis |
2.9% |
| Tinnitus |
2.9% |
|
| Secondary |
| Prophylaxis |
9.7% |
| Infection |
9.3% |
| Onychomycosis |
8.3% |
| Product Used For Unknown Indication |
7.7% |
| Febrile Neutropenia |
6.7% |
| Histoplasmosis |
5.8% |
| Antifungal Prophylaxis |
5.2% |
| Pulmonary Mycosis |
5.2% |
| Bronchopneumopathy |
4.7% |
| Pyrexia |
4.7% |
| Chronic Obstructive Pulmonary Disease |
4.5% |
| Drug Use For Unknown Indication |
4.5% |
| Fungal Infection |
4.2% |
| Sepsis |
3.5% |
| Bronchopulmonary Aspergillosis |
3.2% |
| Aspergillosis |
3.0% |
| Intentional Overdose |
3.0% |
| Lung Infection |
2.5% |
| Diabetes Mellitus |
2.3% |
| Vulvovaginal Candidiasis |
2.2% |
|
| Respiratory Distress |
13.7% |
| Weight Increased |
8.5% |
| Septic Shock |
7.7% |
| Vomiting |
6.0% |
| Death |
5.1% |
| Oedema |
5.1% |
| Pericardial Effusion |
5.1% |
| Pyrexia |
5.1% |
| Renal Failure Acute |
5.1% |
| Sopor |
4.3% |
| Cardiac Failure |
3.4% |
| Cardiac Failure Congestive |
3.4% |
| Hyperbilirubinaemia |
3.4% |
| Malaise |
3.4% |
| Pancreatitis |
3.4% |
| Plantar Fasciitis |
3.4% |
| Sepsis |
3.4% |
| Stomatitis |
3.4% |
| Vulvovaginal Candidiasis |
3.4% |
| Weight Decreased |
3.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
27.1% |
| Product Used For Unknown Indication |
13.7% |
| Pain |
5.3% |
| Non-hodgkin's Lymphoma |
5.2% |
| Hiv Infection |
4.8% |
| Peripheral T-cell Lymphoma Unspecified |
4.0% |
| Prophylaxis |
4.0% |
| Metastases To Bone |
3.7% |
| Gastrooesophageal Reflux Disease |
3.6% |
| Diffuse Large B-cell Lymphoma |
3.2% |
| Crohn's Disease |
3.1% |
| Asthma |
2.9% |
| Diabetes Mellitus |
2.9% |
| Osteoporosis |
2.7% |
| Anxiety |
2.6% |
| Bronchopneumonia |
2.5% |
| Lung Transplant |
2.3% |
| Multiple Myeloma |
2.3% |
| Bronchopneumopathy |
2.1% |
| Acute Myeloid Leukaemia |
2.0% |
|
| Pyrexia |
9.8% |
| Weight Decreased |
9.0% |
| Urinary Tract Infection |
7.5% |
| Sepsis |
6.8% |
| Weight Increased |
6.0% |
| Wound Drainage |
6.0% |
| Psoriasis |
5.3% |
| Therapeutic Agent Toxicity |
5.3% |
| Vomiting |
5.3% |
| Histoplasmosis |
4.5% |
| Squamous Cell Carcinoma |
4.5% |
| Death |
3.8% |
| Phlebitis |
3.8% |
| Transplant Rejection |
3.8% |
| Upper Respiratory Tract Infection |
3.8% |
| Febrile Neutropenia |
3.0% |
| Pain In Extremity |
3.0% |
| Pregnancy |
3.0% |
| Renal Failure |
3.0% |
| Renal Failure Acute |
3.0% |
|
| Interacting |
| Product Used For Unknown Indication |
46.3% |
| Asthma |
11.4% |
| Atypical Mycobacterial Infection |
6.5% |
| Cystic Fibrosis |
6.5% |
| Cellulitis |
3.3% |
| Essential Hypertension |
3.3% |
| Fungal Infection |
3.3% |
| Hypercholesterolaemia |
3.3% |
| Onychomycosis |
3.3% |
| Arthritis |
1.6% |
| Aspergillus Infection |
1.6% |
| Chronic Sinusitis |
1.6% |
| Pseudomonas Infection |
1.6% |
| Pulmonary Embolism |
1.6% |
| Antibiotic Prophylaxis |
0.8% |
| Anxiety |
0.8% |
| Atrial Fibrillation |
0.8% |
| Bronchopulmonary Aspergillosis Allergic |
0.8% |
| Cerebrovascular Accident Prophylaxis |
0.8% |
| Constipation |
0.8% |
|
| Drug Interaction |
28.6% |
| Myositis |
9.5% |
| Scedosporium Infection |
9.5% |
| Uveitis |
9.5% |
| Vomiting |
9.5% |
| International Normalised Ratio Increased |
4.8% |
| Malignant Neoplasm Progression |
4.8% |
| Myalgia |
4.8% |
| Nausea |
4.8% |
| Renal Failure |
4.8% |
| Sinusitis |
4.8% |
| Vision Blurred |
4.8% |
|
